Warner Chilcott (NASDAQ: WCRX)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group in a research note issued to investors on Monday. They currently have a $16.00 price target on the stock, up from their previous price target of $15.00.

The analysts wrote, “WCRX easily beat estimates for the 4th straight Q but we’re still talking about a melting ice-cube for now, and Q4 did benefit from Asacol stocking that will reverse. Recent ’13 guidance does seem conservative given WCRX likely has more OPEX leverage. We tweak up target to $16 on higher ’14-’15 ests., and maintain a ‘Buy’ given undisclosed pipeline and BD potential, but we’d watch out for franchise leakage in the Delzicol switch.”

A number of other analysts have also recently weighed in on WCRX. Analysts at RBC Capital cut their price target on shares of Warner Chilcott from $21.00 to $19.00 in a research note to investors on Wednesday, February 13th. Separately, analysts at UBS AG cut their price target on shares of Warner Chilcott from $24.00 to $23.00 in a research note to investors on Monday, February 11th. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Warner Chilcott from $15.00 to $18.00 in a research note to investors on Monday, February 11th. They now have a “buy” rating on the stock.

Twelve analysts have rated the stock with a buy rating, four have assigned a hold rating, and one has issued a sell rating to the stock. Warner Chilcott has a consensus rating of “overweight” and a consensus price target of $19.46.

Warner Chilcott traded down 2.04% on Monday, hitting $13.675. Warner Chilcott has a 52-week low of $10.85 and a 52-week high of $23.28. The stock’s 50-day moving average is currently $13.75. The company has a market cap of $3.391 billion and a price-to-earnings ratio of 8.67.

Warner Chilcott last issued its quarterly earnings data on Friday, February 22nd. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by $0.23. The company had revenue of $612.00 million for the quarter, compared to the consensus estimate of $565.21 million. During the same quarter last year, the company posted $0.95 earnings per share. Warner Chilcott’s revenue was down 5.3% compared to the same quarter last year. On average, analysts predict that Warner Chilcott will post $3.92 earnings per share for the current fiscal year.

Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America.